Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas

NCT07455032 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Squamous Cell Carcinoma of Head and Neck

Interventions

BIOLOGICAL: intradermal injection of CADI-05
BIOLOGICAL: Pembrolizumab

Sponsor

Fox Chase Cancer Center

Collaborators

[object Object]